SpringWorks Therapeutics Azioni (NASDAQ: SWTX) prezzo delle azioni, notizie, grafici, ricerca sulle azioni, profilo.

SpringWorks Therapeutics (NASDAQ:SWTX) Azioni Citazioni e riassunti delle notizie

SpringWorks Therapeutics

SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

As of Nov. 1, 2024, two stocks in the utilities sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.  
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Entergy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>)</h3>
<ul>
<li>On Oct. 31, Entergy reported better-than-expected quarterly earnings and raised FY24 EPS outlook.. &#8220;We achieved outstanding results across operational, regulatory, resilience, and growth dimensions,&#8221; said Drew Marsh, Entergy Chair and Chief Executive Officer. &#8220;These outcomes are the result of strong execution and leveraging a stakeholder engagement model that starts with the customer and ensures value is created for all stakeholders.&#8221; The company's stock gained around 16% over the past month and has a <a href="https://www.benzinga.com/quote/ETR">52-week high of $156.85</a>.</li>
<li>RSI Value: 90.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ETR Price Action: Shares of Entergy gained 15.2% to close at $154.78 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Xcel Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>)</h3>
<ul>
<li>On Oct. 31, Xcel Energy posted downbeat quarterly earnings. &#8220;The U.S. energy industry is on the cusp of its biggest transition in a century,&#8221; said Bob Frenzel, chairman, president and CEO of Xcel Energy. &#8220;The unprecedented energy demand to power new technologies, grow U.S.-based manufacturing and support the electrification of our daily lives requires a fundamental shift in how our industry generates and delivers energy, while ensuring our infrastructure is designed to withstand severe weather events and other risks.&#8221; The company's stock gained around 2% over the past five days and <a href="https://www.benzinga.com/quote/XEL">has a 52-week high</a> of $67.73.</li>
<li>RSI Value: 75.43</li>
<li>XEL Price Action: Shares of Xcel Energy gained 6% to close at $66.81 on Thursday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Top 2 Utilities Stocks That May Crash This Quarter

Guidance

UScellular Revises FY24 Service Revenues Outlook From $2.95B- $3.05B To $2.95B - $3.0B

Stephens &amp; Co. analyst Jim Salera maintains Lancaster Colony (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>) with a Equal-Weight and lowers the price target from $200 to $196.

LANC

Stephens & Co. Maintains Equal-Weight on Lancaster Colony, Lowers Price Target to $196

Earnings

FUBO

FuboTC Q3 North America Revenue $377M, Rest Of world Revenue $8.9M

Madison Square Garden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.79) by 60.76 percent. The company reported quarterly sales of $53.307 million which beat the analyst consensus estimate of $43.671 million by 22.06 percent. This is a 23.84 percent increase over sales of $43.046 million the same period last year.

Earnings Beats

MSGS

Madison Square Garden Q1 2025 GAAP EPS $(0.31) Beats $(0.79) Estimate, Sales $53.307M Beat $43.671M Estimate

PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) reported quarterly earnings of $0.42 per share which met the analyst consensus estimate. This is a 2.33 percent decrease over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $2.066 billion which beat the analyst consensus estimate of $1.914 billion by 7.92 percent. This is a 1.13 percent increase over sales of $2.043 billion the same period last year.

PPL Q3 2024 Adj. EPS $0.42, Inline, Sales $2.066B Beat $1.914B Estimate

Alpha Metallurgical Resources Reported Tons Of Coal Sold In Q3 Of 4.1M

CBOE

Cboe Global Markets Raises FY24 Adj. Operating Expenses Guidance From $795M-$805M To $798M-$808M

HC Wainwright &amp; Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) with a Neutral and maintains $12 price target.

Reiteration

ZYME

HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $12 Price Target

Rosenblatt analyst Barton Crockett maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Buy and raises the price target from $261 to $262.

AAPL

Rosenblatt Maintains Buy on Apple, Raises Price Target to $262

Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $1.03 by 71.84 percent. The company reported quarterly sales of $671.897 million which missed the analyst consensus estimate of $672.950 million by 0.16 percent. This is a 9.43 percent decrease over sales of $741.820 million the same period last year.

Earnings Misses

Alpha Metallurgical Q3 2024 GAAP EPS $0.29 Misses $1.03 Estimate, Sales $671.897M Miss $672.950M Estimate

Telephone and Data Q3 2024 Adj. EPS $0.01 Beats $(0.18) Estimate, Sales $1.224B Miss $1.249B Estimate

United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.13 by 100 percent. This is unchanged from the same period last year. The company reported quarterly sales of $922.00 million which missed the analyst consensus estimate of $939.81 million by 1.89 percent. This is a 4.26 percent decrease over sales of $963.00 million the same period last year.

United States Cellular Q3 2024 Adj EPS $0.26 Beats $0.13 Estimate, Sales $922.00M Miss $939.81M Estimate

Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) reported quarterly earnings of $2.22 per share which beat the analyst consensus estimate of $2.19 by 1.37 percent. The company reported quarterly sales of $532.000 million which beat the analyst consensus estimate of $530.762 million by 0.23 percent. This is a 10.72 percent increase over sales of $480.500 million the same period last year.

Cboe Global Markets Q3 2024 Adj. EPS $2.22 Beats $2.19 Estimate, Sales $532.000M Beat $530.762M Estimate

Dominion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.93 by 5.38 percent. This is a 30.67 percent increase over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $3.940 billion which missed the analyst consensus estimate of $4.179 billion by 5.71 percent. This is a 3.41 percent increase over sales of $3.810 billion the same period last year.

Dominion Energy Q3 2024 Adj. EPS $0.98 Beats $0.93 Estimate, Sales $3.940B Miss $4.179B Estimate

FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) reported quarterly sales of $374.732 million which missed the analyst consensus estimate of $376.767 million by 0.54 percent. This is a 20.17 percent increase over sales of $311.822 million the same period last year.

FuboTV Q3 Sales $374.732M Miss $376.767M Estimate

Needham analyst Mayank Tandon maintains Grid Dynamics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDYN#NASDAQ">GDYN</a>) with a Buy and raises the price target from $17 to $20.

GDYN

Needham Maintains Buy on Grid Dynamics Holdings, Raises Price Target to $20

Rosenblatt analyst Hans Mosesmann maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Sell and raises the price target from $17 to $20.

INTC

Rosenblatt Maintains Sell on Intel, Raises Price Target to $20

Baird analyst Mike Polark maintains iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) with a Outperform and lowers the price target from $100 to $79.

IRTC

Baird Maintains Outperform on iRhythm Technologies, Lowers Price Target to $79

Needham analyst Charles Shi maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Buy and lowers the price target from $245 to $230.

ONTO

Needham Maintains Buy on Onto Innovation, Lowers Price Target to $230

Bank of America Securities analyst Alec Stranahan has reiterated their bullish stance on SWTX stock, giving a Buy rating today. Alec Stranahan has ...

Strong Q2 Performance and Promising Drug Pipeline Bolster Buy Rating for Springworks Therapeutics

SpringWorks Therapeutics Recent Developments Move This To Speculative Buy (Upgrade)

Druckenmiller's Duquesne pares Apple, Coupang, adds Adobe, TeraWulf, others

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Springworks Therapeutics (SWTX – Research Report) and keeping the price target...

Buy Rating Affirmed for Springworks Therapeutics on Strong Outlook for Mirdametinib

FDA accepts SpringWorks application for mirdametinib for NF1-PN

FDA accepts SpringWorks' application for mirdametinib for NF1-PN

Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2024 Update

Goldman Sachs analyst Corinne Johnson has reiterated their bullish stance on SWTX stock, giving a Buy rating on August 28. Corinne Johnson has give...

Strong Buy Rating for Springworks Therapeutics as Mirdametinib Shows Promise in NF1-PN Treatment

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target of $68.00...

Springworks Therapeutics: Promising Outlook for Ogsiveo Drives Overweight Rating and Elevated Price Target

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report), with a price t...

TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)

ADBE

ANET

COHR

CPNG

CRESY

DAKT

FLEX

FLUT

GGAL

MELI

MSFT

NTRA

NVDA

NWSA

NWSAL

PDYPY

PLTR

SWTX

WULF

Press Releases

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

Health Care

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

General

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

Management

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

JP Morgan

HC Wainwright & Co.

Barclays

Wedbush

Goldman Sachs

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Crypto continues to boom in 2024. Explore this list of the best cryptocurrencies to invest in this month. Start building your portfolio now!

10 Best Cryptocurrencies to Invest In for November 2024

10 Best Cryptocurrencies to Invest in for October 2024

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Cryptocurrency

$DOGE

$SHIB

Shytoshi Kusama Schools X User Who Said SHIB Will Remain 'Chump Change Meme' Unless It Can Rise Above A Penny: 'Those Who Are Wise Give Us Respect'

Analyst Color

$BTC

$ETH

$MATIC

$XRP

Harris Vs Trump: Crypto Industry Anticipates 'Favorable Regulatory Environment' For Bitcoin And Other Digital Assets After Elections

MSTR

Michael Saylor Says Bitcoin Remedy To Fix Unhealthy Balance Sheets As MicroStrategy Unveils Massive $42B BTC Purchase Plan

Politics

2024 Election Odds On Polymarket, Kalshi Show Trump Will Win: Why They Might Be Wrong

Personal Finance

Chamath Palihapitiya Says Gen-Z Has 'Decoupled' Financial Freedom From Traditional 9-5 Jobs, Betting Instead On Bitcoin

Future Finance Newsletter

acf/page-sidebar-placement

Cryptocurrency /Money Sidebar

Aperto	-
Chiuso	-
Volume / Media	0 / 917.63K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	18.00 - 53.92
Capitalizzazione di mercato	$2.24B
Rapporto P/E	-
Rendimento del dividendo	-
Exchange	NASDAQ
RSI	41
Vendite allo scoperto	20.81%
Periodo di copertura	12.72

Aperto	-
Chiuso	-
Volume / Media	0 / 917.63K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	18.00 - 53.92
Capitalizzazione di mercato	$2.24B
Rapporto P/E	-
Rendimento del dividendo	-
Exchange	NASDAQ
RSI	41
Vendite allo scoperto	20.81%
Periodo di copertura	12.72

Comments

SpringWorks Therapeutics

SpringWorks Therapeutics (SWTX) Previsione

SpringWorks Therapeutics (NASDAQ:SWTX) Azioni Citazioni e riassunti delle notizie

Notizie recenti

Dati finanziari

Trend degli analisti

Valutazione degli analisti

Confronta

FAQ

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Nome

Ricavi Variazioni
Lordo Variazioni
EBITDA Variazioni
EBIT Variazioni
Utili Variazioni